The bat borne viruses sit on the WHO's pandemic preparedness priority list with 40 to 75 percent mortality and no approved treatments, and a Mount Sinai led team has now shown that one antibody in the cocktail disarms them by stabilizing a sugar bearing structure on the virus…
Nipah and Hendra are two bat-borne viruses on the World Health Organization's pandemic-preparedness priority list. They kill 40 to 75 percent of the people they infect, and there is no approved vaccine and no approved treatment for either. Against that vacuum, a team led from Mount Sinai reports in Science Translational Medicine that two fully human antibodies, given as a cocktail, gave hamsters complete protection against both viruses, even when administered after infection had begun. The deeper story is how one of those antibodies actually works. Cryo-electron microscopy, a method that images frozen viruses at near-atomic resolution, showed it does not block the virus's fusion machinery directly. It stabilizes a sugar-bearing structure on the virus surface in a way that locks the particle before it can enter a cell. That is a previously unrecognized way an antibody can neutralize a virus, and, if it holds up in larger animals, it could make Nipah and Hendra harder to escape through mutation.
The viruses, both members of the henipavirus family, emerge from fruit bat reservoirs and have caused repeated, high-mortality outbreaks across South and Southeast Asia and, in Hendra's case, Australia, according to GEN News coverage of the new study. The cocktail combines two lab-made, or monoclonal, antibodies that target different viral surface proteins. The first, called 8G3, binds the receptor-binding protein, designated G, that Nipah and Hendra use to dock with a host cell. The second, called 2A1, binds the fusion protein, designated F, that the virus uses to merge its own membrane with the cell and slip inside, as Medical Xpress summarizes.
The design logic is straightforward. Hit two independent mechanisms at once, and the virus has to mutate two separate proteins at once to escape. What 2A1 actually does to the fusion protein surprised the structural biologists. In a cryo-electron microscopy snapshot, 2A1 did not displace any viral component. It clamped down on a glycan, a sugar-bearing structure attached to the surface of the F protein, holding it in a pre-entry shape, the authors report. The geometry is closer to embracing a sugar on the virus than competing for the cell-entry machinery, which makes 2A1 a different kind of fusion-protein antibody from any previously described against these viruses, and a candidate template for therapeutics designed to slow viral escape.
The hamster data are striking. Animals that received the cocktail and were then challenged with Nipah or Hendra survived without signs of disease, while untreated animals did not. The protection held even when dosing began after the virus had been given, the most consequential claim for a virus that is rarely diagnosed early in the real world, per GEN News. Independent trade press coverage corroborates the headline finding, including The Scientist and Medical Xpress.
The honest limits are equally important. The work is preclinical. Hamsters are not humans. Several antibody therapies that gave complete protection in animal models of other viruses, including early respiratory syncytial virus work, took years of human trials to confirm or revise. There is no human safety, dosing, or efficacy data here. The same structural insight that explains 2A1's potency also means the antibody depends on a specific sugar arrangement on the F protein, which raises the question of whether Nipah or Hendra strains with different glycan decorations could evade it, a caveat the paper itself acknowledges.
There is also a constraint that is more basic. Human survivor samples are scarce. Axel Guzman-Solis, a graduate student at Mount Sinai and a co-author, told The Scientist that the team had to hunt for survivors from past outbreaks to find naturally occurring human antibodies strong enough to engineer a cocktail around. That scarcity shapes what kind of antibody therapy is even possible at this stage of the field.
What to watch next is whether the 8G3 and 2A1 cocktail advances into non-human primate studies and IND-enabling toxicology, the standard gating steps before a first-in-human trial. The paper is indexed at PubMed as record 42268934. The next round of animal studies will determine whether the glycan-stabilization mechanism holds up beyond hamsters, and whether this cocktail can become the first antibody therapy for a pathogen that, despite years of effort, still has no approved human treatment.